1. A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. Issue 3 (5th March 2013) Authors: Gross, Jorge Luiz; Rogers, James; Polhamus, Daniel; Gillespie, William; Friedrich, Christian; Gong, Yan; Monz, Brigitta Ursula; Patel, Sanjay; Staab, Alexander; Retlich, Silke Journal: BMJ open Issue: Volume 3:Issue 3(2013) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Semi‐Physiological Model of Amyloid‐β Biosynthesis and Clearance in Human Cerebrospinal Fluid: A Tool for Alzheimer's Disease Research and Drug Development. (27th May 2013) Authors: Haug, Karin G.; Staab, Alexander; Dansirikul, Chantaratsamon; Lehr, Thorsten Journal: Journal of clinical pharmacology Issue: Volume 53:Number 7(2013:Jul.) Page Start: 691 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Issue 5 (14th December 2006) Authors: Díaz-González, Federico; Alten, Rieke H E; Bensen, William G; Brown, Jacques P; Sibley, John T; Dougados, Maxime; Bombardieri, Stefano; Durez, Patrick; Ortiz, Pablo; de-Miquel, Gonzalo; Staab, Alexander; Sigmund, Ralf; Salin, Laurence; Leledy, Caroline; Polmar, Stephen H Other Names: group-author. Journal: Annals of the rheumatic diseases Issue: Volume 66:Issue 5(2007) Page Start: 628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Exposure−response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes. (December 2014) Authors: Riggs, Matthew M.; Seman, Leo J.; Staab, Alexander; MacGregor, Thomas R.; Gillespie, William; Gastonguay, Marc R.; Woerle, Hans J.; Macha, Sreeraj Journal: British journal of clinical pharmacology Issue: Volume 78:Number 6(2014:Dec.) Page Start: 1407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. (17th February 2016) Authors: Borghardt, Jens Markus; Weber, Benjamin; Staab, Alexander; Kunz, Christina; Formella, Stephan; Kloft, Charlotte Journal: British journal of clinical pharmacology Issue: Volume 81:Number 3(2016:Mar.) Page Start: 538 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Modeling Exposure‐Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib. (27th February 2019) Authors: Niebecker, Ronald; Maas, Hugo; Staab, Alexander; Freiwald, Matthias; Karlsson, Mats O. Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 8:Number 4(2019) Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Model‐based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. (23rd June 2016) Authors: Borghardt, Jens Markus; Weber, Benjamin; Staab, Alexander; Kunz, Christina; Kloft, Charlotte Journal: British journal of clinical pharmacology Issue: Volume 82:Number 3(2016:Sep.) Page Start: 739 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives. (1st February 2019) Authors: Marshall, Scott; Madabushi, Rajanikanth; Manolis, Efthymios; Krudys, Kevin; Staab, Alexander; Dykstra, Kevin; Visser, Sandra A.G. Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 8:Number 2(2019) Page Start: 87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. (13th August 2013) Authors: Riggs, Matthew M.; Staab, Alexander; Seman, Leo; MacGregor, Thomas R.; Bergsma, Timothy T.; Gastonguay, Marc R.; Macha, Sreeraj Journal: Journal of clinical pharmacology Issue: Volume 53:Number 10(2013:Oct.) Page Start: 1028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗